1. Apple in 30 seconds, and where it stands in biosensors

2. The logo and how the name is written

3. Where the company sits in the field

Apple's main category is wearables & consumer devices. It is not a company that makes sensors from raw materials; it is a company that puts biosignal sensors into its own general-purpose device and creates value with software that analyzes the signals. We assign no secondary category: Apple has no continuous glucose monitor and no in vitro diagnostic instrument of its own Our calculation. As our explainers on wearable biosensors and on regulatory categories for medical devices and home use describe, the regulatory burden depends on what is measured and what is claimed. In Apple's case, features submitted to the FDA were authorized or cleared for narrowly defined uses and populations, while functions that were not submitted are labelled "not for medical use" Sourced.

4. Scale

Apple is a very large company, and the company as a whole is not the subject here. We give group-wide figures briefly and cover what bears on biosensors from Section 5 onward.

The fiscal year ends in late September (fiscal 2025 ended 27 September 2025). Apple had approximately 166,000 full-time equivalent employees as of 27 September 2025 Sourced. The Wearables, Home and Accessories category covers smartwatches, wireless headphones, the Apple Vision Pro spatial computer, home products and accessories, and sales of the Apple Watch alone are not disclosed. The 10-K attributes the fiscal 2025 decline to lower sales of Accessories and Wearables. In the third quarter of fiscal 2026 (April-June 2026) the category was US$7,883 million (US$7,404 million a year earlier, up 6%), and the nine months to that quarter totalled US$27,277 million (US$26,673 million a year earlier, up 2%) Sourced.

5. Resources committed to biosensors (including the regulatory position)

Apple does not disclose staffing, spending or investment limited to biosensors. The table below shows, for four viewpoints, what primary sources confirm and what they do not ("not stated" is itself a finding).

Regulatory position (as far as FDA public documents confirm)

The table below lists eight biosignal-related records found in the FDA 510(k) database (openFDA) under applicants whose name contains "Apple", plus the functions for which we could not confirm any authorization or clearance. De Novo authorization (classification of a new type of low-to-moderate-risk device), 510(k) clearance (substantial equivalence to an existing device) and PMA approval are separate pathways. We found no PMA record for the applicant name "Apple" in the openFDA PMA search Sourced. All are premarket decisions, and the uses, populations and limitations are those stated in the FDA documents.

6. What it has done so far

7. What comes next

Primary sources also contain the following Not yet confirmed.

• The September 2026 announcement puts the "Health Sensing System" behind features such as readiness and Health Age. Apple describes readiness as a single 0-10 score calculated from activity, training load, vitals and sleep score (we could not confirm an FDA category for it).
• The footnote of the September 2026 announcement still says the Vitals app is "for wellness purposes only and not for medical use". Whether new features built on the same sensors will obtain medical authorization is not confirmed.
• The FDA document for the hypertension feature says its PCCP does not include adaptive algorithms that continue to learn in the field: modified algorithms are trained, tuned and locked before release. Users are to be informed of changes through updates to the Instructions for Use.

8. What the company is aiming for in biosensors

We separate what the company says directly from what we read into it. Inference marks our interpretation of primary sources; it is not something the company has said.

9. Map of partnerships in biosensors

The collaborations and cooperation that Apple makes public are limited to those in ClinicalTrials.gov and Apple's press releases. Neither the 10-K nor the biosensor-related materials name component makers, sensor-material suppliers or contract manufacturers Sourced. We therefore cannot draw a material or component supply chain (the 10-K says only, in general terms, that some key components come from single or limited sources). Note that "predicate" in the figure refers to another company's device used as a benchmark in regulatory documents; it is not a partnership.

10. Technologies, products and services

The official Apple Watch specifications describe the sensor set as follows. Because conditions differ by product, we give no performance figures except those in FDA documents.

These values come from different studies with different references and populations, and they do not show which feature is better than another. The FDA documents state for every feature that the absence of a notification does not mean the absence of disease Sourced.

11. The risks this company carries

12. Glossary

13. References

1. Apple Form 10-K for the fiscal year ended September 27, 2025 (filed with the SEC on 31 October 2025). Company profile, sales, Wearables, Home and Accessories, R&D, employees, component sourcing, regulatory and data risks. https://www.sec.gov/Archives/edgar/data/320193/000032019325000079/aapl-20250927.htm
2. Apple Form 10-Q for the quarterly period ended June 27, 2026 (filed 31 July 2026). Wearables, Home and Accessories and R&D for the third quarter and nine months of fiscal 2026. https://www.sec.gov/Archives/edgar/data/320193/000032019326000020/aapl-20260627.htm
3. U.S. Food and Drug Administration (FDA) De Novo Classification Request for ECG App (DEN180044), decision summary. Use, sensitivity and specificity, clinical study, special controls. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180044.pdf
4. U.S. Food and Drug Administration (FDA) De Novo Classification Request for Irregular Rhythm Notification Feature (DEN180042), decision summary. Use, limitations, PPG principle, skin-tone testing, clinical study. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180042.pdf
5. U.S. Food and Drug Administration (FDA) 510(k) K201525 (ECG 2.0 App): clearance letter and 510(k) summary, 8 October 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201525.pdf
6. U.S. Food and Drug Administration (FDA) 510(k) K212516 (IRNF App): clearance letter and 510(k) summary, 22 October 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K212516.pdf
7. U.S. Food and Drug Administration (FDA) 510(k) K213971 (Atrial Fibrillation History Feature): clearance letter and 510(k) summary, 3 June 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K213971.pdf
8. U.S. Food and Drug Administration (FDA) 510(k) K231173 (Irregular Rhythm Notification Feature): clearance letter and 510(k) summary, 21 July 2023. Implementation of a PCCP. https://www.accessdata.fda.gov/cdrh_docs/pdf23/K231173.pdf
9. U.S. Food and Drug Administration (FDA) 510(k) K240929 (Sleep Apnea Notification Feature): clearance letter and 510(k) summary, 13 September 2024. Predicate DEN230041, clinical study. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240929.pdf
10. U.S. Food and Drug Administration (FDA) 510(k) K250507 (Hypertension Notification Feature): clearance letter and 510(k) summary, 11 September 2025. Predicate DEN230003, clinical study, PCCP. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250507.pdf
11. U.S. Food and Drug Administration (FDA) Do Not Use Smartwatches or Smart Rings to Measure Blood Glucose Levels: FDA Safety Communication (21 February 2024). https://www.fda.gov/medical-devices/safety-communications/do-not-use-smartwatches-or-smart-rings-measure-blood-glucose-levels-fda-safety-communication
12. Apple Newsroom Apple debuts Apple Watch Series 11, featuring groundbreaking health insights (9 September 2025). Status of hypertension notifications at announcement. https://www.apple.com/newsroom/2025/09/apple-debuts-apple-watch-series-11-featuring-groundbreaking-health-insights/
13. Apple Newsroom Introducing Apple Watch Series 12, with the all-new Health Sensing System (9 September 2026). New sensors, readiness, the Health app, footnotes. https://www.apple.com/newsroom/2026/09/introducing-apple-watch-series-12-with-the-all-new-health-sensing-system/
14. Apple Apple Watch Series 12 Tech Specs. Sensor set, and footnotes stating that Blood Oxygen, temperature and Vitals are not for medical use. https://www.apple.com/apple-watch-series-12/specs/
15. Apple Support How to use the Blood Oxygen app on Apple Watch. Not for medical use, age 18 and over, availability by country. https://support.apple.com/en-us/120358
16. ClinicalTrials.gov NCT03335800 Apple Heart Study (419,927 participants; collaborator Stanford University). https://clinicaltrials.gov/study/NCT03335800
17. ClinicalTrials.gov NCT03492554 Electrocardiogram Clinical Validation Study (602 participants; collaborator IQVIA Pty Ltd). https://clinicaltrials.gov/study/NCT03492554
18. ClinicalTrials.gov NCT04699812 Atrial Fibrillation Algorithms Clinical Validation Study (573 participants; collaborator IQVIA Pty Ltd). https://clinicaltrials.gov/study/NCT04699812
19. ClinicalTrials.gov NCT04198194 Apple Heart & Movement Study (collaborator American Heart Association). https://clinicaltrials.gov/study/NCT04198194
20. ClinicalTrials.gov NCT06958523 Apple Health Study (collaborators Brigham and Women's Hospital and MCRA). https://clinicaltrials.gov/study/NCT06958523
21. Apple Newsroom Apple advances health and fitness capabilities using Apple Intelligence (9 September 2026). Vitals footnote; booking Quest Diagnostics tests. https://www.apple.com/newsroom/2026/09/apple-advances-health-and-fitness-capabilities-using-apple-intelligence/
22. U.S. Food and Drug Administration (FDA) openFDA 510(k) API (search by applicant name "Apple"). Confirms Apple's biosignal records and the absence of a Blood Oxygen record. https://api.fda.gov/device/510k.json?search=applicant:%22Apple%22&limit=100&sort=decision_date:desc
23. U.S. Food and Drug Administration (FDA) openFDA PMA API (search by applicant name "Apple" returned no match). https://api.fda.gov/device/pma.json?search=applicant:%22Apple%22&limit=3
24. ClinicalTrials.gov NCT04247581 ECG App Algorithms Clinical Validation Study (546 participants; collaborator IQVIA Pty Ltd). https://clinicaltrials.gov/study/NCT04247581
25. U.S. Food and Drug Administration (FDA) openFDA device recall API (no match for "Apple Inc"). https://api.fda.gov/device/recall.json?search=recalling_firm:%22Apple%20Inc%22&limit=5
26. Apple Official website apple.com (source of the logo image, specified as the logo in structured data). https://www.apple.com/

14. Claim-to-source audit

Last updated 3 October 2026 / Troy Technical
Figures in this article come from Apple's SEC filings (Form 10-K, Form 10-Q), FDA public documents, Apple's official announcements and product specifications, and ClinicalTrials.gov. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of primary sources, not statements made by the company. This article is not medical advice for any individual reader.